000			02113 a2200589 4500
005			20250516051007.0
264		0	_c20120713
008			201207s 0 0 eng d
022			_a1569-8041
024	7		_a10.1093/annonc/mdr346 _2doi
040			_aNLM _beng _cNLM
100	1		_aBrunnberg, U
245	0	0	_aInduction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. _h[electronic resource]
260			_bAnnals of oncology : official journal of the European Society for Medical Oncology _cApr 2012
300			_a990-6 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAminoglycosides _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Humanized _xadministration & dosage
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aCytarabine _xadministration & dosage
650	0	4	_aDaunorubicin _xadministration & dosage
650	0	4	_aDisease-Free Survival
650	0	4	_aFemale
650	0	4	_aGemtuzumab
650	0	4	_aHumans
650	0	4	_aInduction Chemotherapy
650	0	4	_aLeukemia, Myeloid, Acute _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aSurvival Analysis
650	0	4	_aTreatment Outcome
700	1		_aMohr, M
700	1		_aNoppeney, R
700	1		_aDürk, H A
700	1		_aSauerland, M C
700	1		_aMüller-Tidow, C
700	1		_aKrug, U
700	1		_aKoschmieder, S
700	1		_aKessler, T
700	1		_aMesters, R M
700	1		_aSchulz, C
700	1		_aKosch, M
700	1		_aBüchner, T
700	1		_aEhninger, G
700	1		_aDührsen, U
700	1		_aServe, H
700	1		_aBerdel, W E
773	0		_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 23 _gno. 4 _gp. 990-6
856	4	0	_uhttps://doi.org/10.1093/annonc/mdr346 _zAvailable from publisher's website
999			_c21056195 _d21056195